收费全文 | 1252716篇 |
免费 | 95125篇 |
国内免费 | 1518篇 |
耳鼻咽喉 | 16277篇 |
儿科学 | 40801篇 |
妇产科学 | 34874篇 |
基础医学 | 187641篇 |
口腔科学 | 34678篇 |
临床医学 | 116604篇 |
内科学 | 244180篇 |
皮肤病学 | 27269篇 |
神经病学 | 100934篇 |
特种医学 | 46706篇 |
外国民族医学 | 265篇 |
外科学 | 177972篇 |
综合类 | 25694篇 |
一般理论 | 568篇 |
预防医学 | 103558篇 |
眼科学 | 27943篇 |
药学 | 92109篇 |
6篇 | |
中国医学 | 1952篇 |
肿瘤学 | 69328篇 |
2018年 | 13405篇 |
2017年 | 10335篇 |
2016年 | 11195篇 |
2015年 | 12940篇 |
2014年 | 17961篇 |
2013年 | 27433篇 |
2012年 | 37592篇 |
2011年 | 39959篇 |
2010年 | 22996篇 |
2009年 | 22199篇 |
2008年 | 37752篇 |
2007年 | 40375篇 |
2006年 | 39965篇 |
2005年 | 39073篇 |
2004年 | 37554篇 |
2003年 | 35887篇 |
2002年 | 34798篇 |
2001年 | 55940篇 |
2000年 | 56899篇 |
1999年 | 47742篇 |
1998年 | 12450篇 |
1997年 | 11303篇 |
1996年 | 11709篇 |
1995年 | 11819篇 |
1994年 | 11027篇 |
1993年 | 10319篇 |
1992年 | 38151篇 |
1991年 | 37667篇 |
1990年 | 36431篇 |
1989年 | 35255篇 |
1988年 | 32667篇 |
1987年 | 32020篇 |
1986年 | 30514篇 |
1985年 | 28774篇 |
1984年 | 21912篇 |
1983年 | 19143篇 |
1982年 | 11304篇 |
1981年 | 10261篇 |
1979年 | 20884篇 |
1978年 | 15359篇 |
1977年 | 12710篇 |
1976年 | 11755篇 |
1975年 | 12743篇 |
1974年 | 15520篇 |
1973年 | 15303篇 |
1972年 | 14482篇 |
1971年 | 13519篇 |
1970年 | 12755篇 |
1969年 | 12034篇 |
1968年 | 11203篇 |
Vaccination prevents severe morbidity and mortality from COVID-19 in the general population. The immunogenicity and efficacy of SARS-CoV-2 vaccines in patients with antibody deficiency is poorly understood.
ObjectivesCOVID-19 in patients with antibody deficiency (COV-AD) is a multi-site UK study that aims to determine the immune response to SARS-CoV-2 infection and vaccination in patients with primary or secondary antibody deficiency, a population that suffers from severe and recurrent infection and does not respond well to vaccination.
MethodsIndividuals on immunoglobulin replacement therapy or with an IgG less than 4 g/L receiving antibiotic prophylaxis were recruited from April 2021. Serological and cellular responses were determined using ELISA, live-virus neutralisation and interferon gamma release assays. SARS-CoV-2 infection and clearance were determined by PCR from serial nasopharyngeal swabs.
ResultsA total of 5.6% (n?=?320) of the cohort reported prior SARS-CoV-2 infection, but only 0.3% remained PCR positive on study entry. Seropositivity, following two doses of SARS-CoV-2 vaccination, was 54.8% (n?=?168) compared with 100% of healthy controls (n?=?205). The magnitude of the antibody response and its neutralising capacity were both significantly reduced compared to controls. Participants vaccinated with the Pfizer/BioNTech vaccine were more likely to be seropositive (65.7% vs. 48.0%, p?=?0.03) and have higher antibody levels compared with the AstraZeneca vaccine (IgGAM ratio 3.73 vs. 2.39, p?=?0.0003). T cell responses post vaccination was demonstrable in 46.2% of participants and were associated with better antibody responses but there was no difference between the two vaccines. Eleven vaccine-breakthrough infections have occurred to date, 10 of them in recipients of the AstraZeneca vaccine.
ConclusionSARS-CoV-2 vaccines demonstrate reduced immunogenicity in patients with antibody deficiency with evidence of vaccine breakthrough infection.
相似文献